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Exposure to Phthalate Esters
The American Chemistry Council Phthalate
Esters Panel read with great interest the
paper by Blount et al. (1) regarding urinary
levels of phthalate ester metabolites in a sam-
ple set of the Third National Health and
Nutrition Examination Survey (NHANES
III) population. We have known for some
time of this research, and have provided
whatever information and assistance we
could to the Centers for Disease Control
and Prevention (CDC). The paper presents
some interesting and informative data on the
likely exposure levels of phthalate esters,
which are summarized below:
• We believe that the data are analytically
sound in that the CDC measured a physi-
ologically relevant metabolite of the
phthalate monoester as opposed to many
investigators who have measured phtha-
late diester in biological samples (blood
and tissues) as a biomonitor of exposure.
Measurement of phthalate diesters in bio-
logical samples is highly subject to false
positives from laboratory contamination.
• The CDC data measure urinary concentra-
tions of phthalate monoesters, not the daily
intake of phthalate esters. Although these
measurements establish a good basis for
biomonitoring, further calculations are
needed to relate them to doses (below
which we do not expect to see effects)
developed from animal toxicology studies,
such as U.S. Environmental Protection
Agency (U.S. EPA) reference doses (RfDs),
in order to place them into the risk assess-
ment paradigm. Studies being conducted
by the U.K. Ministry of Agriculture, Food,
and Fisheries provide a key piece of infor-
mation, namely, the molar ratio of phtha-
late ester metabolite in the urine of human
volunteers given known amounts of phtha-
late ester (2). With this information, the
CDC data can be converted to intake levels
using the equation below by substituting
the creatinine-corrected concentrations of
monoester and a maximum output of 20
mg creatinine/kg/day for an adult female
(range of 11–20 mg creatinine/kg/day) (3). 
• Using this conversion, the data indicate that
the 95th percentile value of daily intake in
all cases, except for diethyl phthalate
(DEP), is below the estimated intake values
established by the Agency for Toxic
Substances and Disease Registry (ATSDR;
Atlanta, GA), the International Programme
on Chemical Safety (IPCS; Geneva,
Switzerland), or the European Union (EU)
risk assessment as illustrated in Table 1
(95th percentile vs. estimated intake).
Furthermore, the highest values obtained
(including for DEP) are at or below levels
that the U.S. EPA has determined to be safe
for daily exposures to these phthalates (esti-
mated intake vs. RfD). 
• The highest value for total environmental
exposure to the two most widely used
plasticizers, di-(2-ethylhexyl) phthalate
(DEHP) and di-isononyl phthalate
(DINP), are at or below the levels estimat-
ed by various governmental agencies.
Thus, environmental exposure to the two
phthalate esters used in most polyvinyl
chloride (PVC) consumer products (toys,
shower curtains, etc.) is very low.
• The CDC data also show what appear to
be higher levels of exposure of DEP,
dibutyl phthalate (DBP), and butylbenzyl
phthalate (BBP), a fact that has received
attention. DEP, DBP, and BBP are used
in some personal care products (6,7). Each
of these phthalate esters also has Food and
Drug Administration approved uses in
food packaging and processing materials
(8). Therefore, it is not surprising that uri-
nary levels of these phthalate esters may be
higher relative to those used only in PVC. 
• As indicated by Blount et al. (1), all avail-
able pharmacokinetic data on phthalate
esters indicate that they are rapidly metab-
olized and excreted from the body, and
there is no concern that these materials
bioaccumulate. 
We recognize that the study reported by
Blount et al. (1) is only a pilot project for a
larger-scale biomonitoring program, and we
look forward to the continued research in
this area. We believe the CDC data demon-
strate that environmental exposure to high
molecular weight phthalates is negligible.
For the low molecular weight phthalates,
with potential exposures other than PVC
plastics, the data indicate that exposures are
within previously determined exposure esti-
mates and below developed RfDs. Phthalate
esters have been used for more than 50 years
(nearly 100 years in the case of DBP) with-
out direct evidence of adverse human health
effects. Although there are data for effects in
rodents after exposure to phthalate esters,
there are significant differences between
rodents and primates in the pharmacokinet-
ics and effects of these substances. 
Raymond M. David
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Human Exposure Estimates
for Phthalates
Phthalates are important industrial chemi-
cals used in a variety of applications. These
chemicals can be ingested, inhaled, or
absorbed through the skin, resulting in
human exposure and raising significant
public health concerns. 
Blount et al. (1) provide the first sys-
tematic compilation of data that address
exposures of the general population to com-
mercially important phthalate diesters. The
data result from a study conducted at the
Centers for Disease Control and Prevention/
National Center for Environmental Health
(CDC/NCEH) that is part of a continuing
Daily intake mg/kg/day
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Table 1. Intake levels. 
Phthalate GM 95th Percentile Highest value Estimated intake RfD
DEP 12.34a 93.33 242.81 57b 800
DBP 1.56 6.87 116.96 7 100
BBP 0.73 3.34 19.79 6 200
DEHP 0.60 3.05 38.48 30c 20
DINP 0.21 1.08 14.35 10.8 ND
ND, not determined. aAll values in µg/kg/day based on a maximum creatinine clearance of 20 mg/kg/day. bEstimated
intake taken from ATSDR, IPCS, or EU draft risk assessments. cFrom Doull et al. (4) using ATSDR estimates.collaboration with the National Institute of
Environmental Health Sciences/National
Toxicology Program (NIEHS/NTP). The
study was designed to assess human tissue
levels of potential or known environmental
toxicants using biological samples collected
through CDC’s NHANES program and
state-of-the-art analytical methods. Such
data will aid the NTP in identifying chemi-
cals in need of toxicologic evaluation, based
on their prevalence in human tissues, as well
as providing useful human exposure infor-
mation on high priority toxic chemicals
identified through the NTP or other toxico-
logic testing activities.
The primary route of human phthalate
exposure to the general population has been
presumed to be ingestion. Lower molecular
weight phthalates can be absorbed percuta-
neously, and the more volatile congeners can
be inhaled. Lipases in the intestinal epitheli-
um, liver, and other tissues hydrolyze the
diester to a monoester, which is systemically
distributed. Some of the monoester is con-
verted into other chemical species by oxida-
tive metabolism in bodily tissues, and some
of it is excreted in the urine as acyl glu-
curonides. The extent of oxidative metabo-
lism and conjugation would be expected to
vary among chemicals, species, and individu-
als. Blount et al. (1) report the concentra-
tions of seven phthalate monoesters in the
urine of 289 people. We present here the
results of calculations of the estimated total
daily intake of phthalates that would result
in the reported urinary concentrations of
monoester metabolites. These intake esti-
mates can be used as a measure of total expo-
sure to these phthalates and compared with
previous intake estimates determined from
levels in environmental media.
The daily exposure can be estimated by
using a linear two-compartment model. The




where FE and FU are the total and urinary
fractions of the dose eliminated in time t,
and ktotal and ku are the apparent first-order
rate constants for total elimination and
elimination of urinary monoester, respec-
tively. The two rate constants were calculat-
ed from the excreted fractions observed
during the 24 hr following a single oral
dose of diester, using Equations 1 and 2.
Assuming steady-state intake and meta-
bolic clearance of the diester, the internal
exposure rate for an individual is approxi-
mated by
[3]
where ME is the urinary concentration of
monoester per gram creatinine, CE is the
creatinine excretion rate normalized by body
weight, f is the ratio of urinary excretion to
total elimination (ku/ktotal), and MWd and
MWm are the molecular weights of the
diesters and monoesters, respectively. We
calculated the intake for each individual in
the reference population using Equation 3.
The presumed parent compound for urinary
monoesters generally is the corresponding
symmetrical diester. The presumed parent
compound of urinary monobenzyl phthalate
is n-butyl benzyl phthalate.
Published animal or human data for
excretion of metabolites of di-n-butyl
phthalate (2,3), n-butyl benzyl phthalate
(4,5), di(2-ethylhexyl) phthalate (6,7), and
di-n-octyl phthalate (8) allowed calculation
of the fractional excretion values. The frac-
tion of the dose of diethyl phthalate appear-
ing as urinary monoethyl phthalate was
assumed to be the same as for the di-n-butyl
congener. The fraction of n-butyl benzyl
phthalate excreted as benzyl phthalate was
adjusted using the observation that this
monoester accounts for 64% of the urinary
metabolites (9). The fraction found for
di(2-ethylhexyl) phthalate was used for dicy-
clohexyl and di-i-nonyl phthalates as well
because specific fractions could not be
found for these diesters. The fractional
excretion values used in our calculations are
shown in Table 1. Creatinine excretion was
set to 23 and 18 mg/kg/day for men and
women, respectively (10). 
The NTP Center for the Evaluation of
Risks to Human Reproduction (CERHR)
conducts scientific evaluations of the litera-
ture on the reproductive and developmental
toxicity of selected chemicals to which peo-
ple are exposed. In Table 2, our intake esti-
mates are compared to general population
exposures estimated by the Phthalates
Expert Panel of the CERHR based on pub-
lished data. Because several phthalates have
been shown to be developmental toxicants
in laboratory studies, exposures of the 97
women of reproductive age (20–40 years) in
the total sample and of the remaining indi-
viduals were calculated separately. These
results are compared in Table 3. Excretion
levels of the metabolites that were below the
limit of detection (LOD; 1 ng analyte/mL
urine) were assumed to be zero.
Uncertainties in the values of the para-
meters in Equations 1 and 2 are potential
sources of error in our estimates of expo-
sure. Creatinine excretion is known with
10% accuracy (10). FE is generally accurate
intake g / kg / day
ME g / g CE mg / kg / day
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Table 1. Total fractional excretion (FE) and fractional urinary excretion of monoester (FU) during 24 hr
after a single oral dose of diester.
Monoester Diester FE FU
Ethyl Diethyl 0.94a 0.52a
n-Butyl Di-n-butyl 0.94b 0.52c
Benzyl n-Butyl benzyl 0.70d 0.36e
Cyclohexyl Dicyclohexyl 0.65f 0.069f
2-Ethylhexyl Di(2-ethylhexyl) 0.65g 0.069h
n-Octyl Di-n-octyl 0.65f 0.043i
i-Nonyl Di-i-nonyl 0.65f 0.069f
aAssumed to be the same as di-n-dibutyl phthalate. bData from Tanaka et al. (2). cData from Foster et al. (3). dData for the
urinary fraction from Nativelle et al. (4); data for the fecal fraction from Eigenberg et al. (5). eAdjusted value from
Nativelle et al. (4) for observed urine content (9). fAssumed to be the same as di(2-ethylhexyl) phthalate. gData for the uri-
nary fraction from Peck and Albro (7); data for the fecal fraction from Kluwe (6). hData from Peck and Albro (7). iData from
Albro and Moore (8).
Table 2. Estimated exposures (mg/kg/day) to the general population based on extrapolated intake from
urinary metabolites (Equation 1) in 289 individuals measured by Blount et al. (1).
Monoester Diester Minimum Median 95th percentile Maximum CERHRa
Ethyl Diethyl <  LOD 12 110 320 NA
n-Butyl Di-n-butyl 0.084 1.5 7.2 110 2–10b
Benzyl n-Butyl benzyl 0.094 0.88 4.0 29 2c
Cyclohexyl Dicyclohexyl < LOD 0.026 0.25 2.3 NA
2-Ethylhexyl Di(2-ethylhexyl) < LOD 0.71 3.6 46 3–30
n-Octyl Di-n-octyl < LOD 0.0096 0.96 13 < 3– < 30d
i-Nonyl Di-i-nonyl < LOD < LOD 1.7 22 < 3– < 30d
aThe CERHR Phthalates Expert Panel held its third and final meeting on 12–13 July 2000 in Arlington, Virginia; the CERHR
final reports on the seven phthalates evaluated, along with a full description of the center and its activities, are available
on the CERHR web site (11). bThe upper bound for occupational exposure was estimated as 286 µg/kg/day; the estimate of
2 µg/kg/day is at the 84th percentile of our calculated values. cThe CERHR estimate for n-butyl benzyl phthalate is at the
11th percentile of our calculated values. dDi-n-octyl and di-i-nonyl phthalate estimates from the CERHR were reported as
less than for di(2-ethylhexyl) phthalate.A 442 VOLUME 108 | NUMBER 10 | October 2000 • Environmental Health Perspectives
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to approximately 50% (4,5). FU can vary
15-fold among species, with humans in the
middle of the range (12). This variability is
an order of magnitude higher than the
reproducibility of the same measurement
among laboratories (4–6,12). Owing to the
lack of human excretion data, fractional
excretion values for the rat were used for
some congeners. Therefore, our exposure
estimates are probably reliable within an
order of magnitude.
Exposures for the general population,
estimated by the CERHR Phthalates Expert
Panel from published data, are in good
agreement with our calculated human daily
intake estimates based on CDC median val-
ues and presented in Table 2. However, the
maximal values of excreted monoesters (1)
indicate that some individual exposures are
substantially higher than previously estimat-
ed for the general population.
Women of reproductive age appear to
be exposed to higher levels of di-n-butyl
phthalate than are the remainder of the
study population. This is particularly evi-
dent in the 95th percentile column for
n-butyl phthalate in Table 2, where the
estimated exposure values for women
20–40 years of age are approximately 5
times greater than the corresponding values
for the other 192 individuals in the study.
The data reported by Blount et al. (1)
will certainly lead to further efforts to
derive accurate estimates of human expo-
sures based on urinary metabolite levels. In
addition, their data lead to several questions
that should be addressed in the immediate
future; for example: 
• What are the sources and circumstances of
exposure that result in a higher urinary
level of diethyl phthalate metabolites than
of the other six phthalates studied?
• What is the evidence for reproductive and
developmental toxicity of diethyl phthalate?
• What are the sources and circumstances of
exposure that result in some women of
reproductive age having higher urinary lev-
els of n-butyl phthalate than the remainder
of the study population?
• At what levels are humans exposed to other
phthalates not included in this study?
It is important that answers to these and
related questions be pursued by public
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Antitumor Effects of THC 
1-Trans-delta9-tetrahydrocannabinol
(THC), the main active component of mar-
ijuana, has been shown to exhibit anticancer
activity (1,2). Galve-Roperh et al. (1) report-
ed that intratumoral administration of THC
induces apoptosis of transformed neural cells
in culture, and also induces a considerable
regression of malignant gliomas in Wistar
rats and in mice deficient in recombination
activating gene 2. These authors suggest that
their “results may provide the basis for a
new therapeutic approach for the treatment
of malignant gliomas.” Regarding this inter-
esting finding, we believe it is important to
highlight the previous National Toxicology
Program’s long-term in vivo bioassay results
that showed definite antitumor activity of
THC (3,4). This also appears relevant to
the current controversy, at least in the
United States, regarding the use of mari-
juana in clinical medicine. 
Experimentally, groups of 60–70 male
and female rats were administered 0, 12.5,
25, or 50 mg THC/kg body weight (bw),
and male and female mice were given 0,
125, 250, or 500 mg THC/kg bw in corn
oil by gavage for 104–106 weeks (3,4).
During this 2-year period, individual ani-
mal body weights were reduced compared
to controls, although all groups consumed
the same amounts of food. More impor-
tantly, survival in all THC groups of male
and female rats was significantly greater
than the controls. For mice, survival was
comparable among groups except for the
high-dose males. Clinical findings in the
THC groups included lethargy followed by
hyperactivity, convulsions, and seizures,
which occurred typically during and imme-
diately after dosing or handling. 
In both rats and mice, no increased inci-
dences of neoplasms were considered related
to the administration of THC (3,4). In fact,
for several organ systems the incidences of
background tumors in these strains were actu-
ally reduced. The incidences of mammary
gland fibroadenomas and uterine stromal
Table 3. Comparison of estimated exposures (µg/kg/day) to 97 women aged 20–40 years to the rest of the
population (192 individuals)a based on extrapolated intake from urinary metabolites (Equation 1) measured
by Blount et al. (1).
Monoester Diester Minimum Median 95th percentile Maximum
Ethyl Diethyl  0.90 13 90 170
< LOD 11 130 320
n-Butyl Di-n-butyl 0.24 1.7 32 113
0.084 1.4 6.5 50
Benzyl n-Butyl benzyl 0.094 1.2 4.5 7.8
0.11 0.78 3.4 29
Cyclohexyl Dicyclohexyl < LOD 0.051 0.24 0.45
0.012 0.25 2.3
2-Ethylhexyl Di(2-ethylhexyl) < LOD 0.71 3.8 10
0.71 3.5 46
n-Octyl Di-n-octyl < LOD < LOD 0.65 1.5
0.015 1.0 13
i-Nonyl Di-i-nonyl < LOD < LOD 3.7 7.8
1.4 22
aValues for women aged 20–40 years in boldface; remaining values are for the rest of population. Environmental Health Perspectives • VOLUME 108 | NUMBER 10 | October 2000 A 443
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polyps were decreased in THC groups of
female rats, as were incidences of pituitary
gland adenomas, interstitial cell adenomas of
the testis, and pancreatic adenomas in THC-
treated male rats. Concerning nonneoplastic
lesions in mice, increases of thyroid gland fol-
licular cell hyperplasia occurred in all THC
groups, and increases of forestomach hyper-
plasia and ulcers occurred in THC groups of
male mice; yet, no THC-related tumors were
observed to progress from these toxic lesions.
This common lack of correlation between
toxicity and carcinogenicity has long been
known (5–7). Regarding carcinogenic activity
of THC in mice, thyroid gland follicular cell
adenomas were somewhat increased only in
the lowest THC-dosed group of mice (125
mg/kg); thyroid gland follicular cell adenomas
were found in 0/62 control males versus 6/60,
3/61, and 1/57 mice treated with 125, 250,
and 500 mg THC/kg bw, respectively, and in
4/60 control females versus 9/60, 3/60, and
1/60 mice); these were considered not signifi-
cantly related to THC (3,4). However, there
were significant decreases observed for both
benign and malignant liver tumors in male
and female mice. 
The reduced body weights in these
long-term studies may have been contribu-
tory to the lowered tumor rates (8–10), as
most of the reductions in tumor incidences
occurred in hormone-controlled organs
(11). This should not detract from the
overall antitumor effects of THC observed
in both sexes of these species and strains.
Until further studies are accomplished,
these reductions in tumor incidences in six
organs should be considered caused by or
associated with administration of THC. 
Our 2-year studies (3,4) showed that the
observed THC antitumor effects are not
confined to the site of injection or adminis-
tration, and these antitumor effects seem to
affect a range of “spontaneous” tumors
commonly found in rats and mice.
Consequently, the THC-associated antitu-
mor effects are systemically active and are
applicable to different tumor types at differ-
ent organ sites. Again, this lack of specificity
might lend credence to the notion that these
effects are hormonally mediated and likely
related to the observed decreases in body
weights. Nonetheless, there were significant
reductions in total benign and malignant
tumors in all organs combined for both
species after THC exposure: in male rats,
tumors were found in 98% of controls ver-
sus 98, 92, and 90% of groups treated with
12.5, 25, and 50 mg THC/kg bw, respec-
tively; in female rats, tumors were found in
88% of controls versus 82, 86, and 70% of
treated groups. Most strikingly, in male
mice tumors were found in 73% of controls
versus 55, 44, and 30% of male mice treat-
ed with 0, 125, 250, and 500 mg THC/kg
bw, respectively, and in female mice, tumors
were found in 77% of controls versus 52,
43, and 27% of treated groups (3,4). 
Interestingly, the dose levels used by
Galve-Roperh et al. (1) were similar to
those used in our studies (3,4). Their find-
ings also agreed with ours in that THC
administration did not affect either food or
water intake or hematologic profiles and
general clinical chemistry of the animals.
Perhaps further animal bioassay studies
should be done to learn more about the anti-
tumor effects of THC. For example, animals
could be exposed to known carcinogens
(e.g., 9,10-dimethylbenz[a]anthracene expo-
sure resulting in mammary gland tumors) to
determine if THC would block this carcino-
genic activity, or transgenic animals (12,13)
could be used in an attempt to better clarify
the mechanism(s) of THC anticarcinogenic
activity. More definition of dose-response–
antitumor activity relations would be useful,
as would studies using paired feeding, to bet-
ter define the influence of reduced body
weight on tumor incidences. 
With respect to genetic toxicology (4),
THC was not mutagenic in Salmonella
typhimurium strains TA97, TA98, TA100,
or TA1535 with or without rat and ham-
ster liver S9 fractions. In cultured Chinese
hamster ovary (CHO) cells, THC induced
sister chromatid exchanges at the highest
dose tested in the presence of S9; at this
dose level, cell cycle delay indicative of toxi-
city was observed. THC did not induce
chromosomal aberrations in cultured CHO
cells with or without S9 metabolic activa-
tion enzymes. In vivo, no increase in the
frequency of micronucleated erythrocytes
was observed in the peripheral blood of
male or female mice administered THC by
gavage for 13 weeks. Accordingly, THC
does not appear to be genotoxic. 
Long-term carcinogenesis bioassays have
historically and traditionally been used pri-
marily to identify those agents that cause
cancer in laboratory animals and hence
determine which agents represent a signifi-
cant cancer risk to humans exposed to these
carcinogens (14–16). Conversely, these
bioassays can and should also be used to
identify potential anticarcinogenic agents
(17–19). Thus, in our studies, rats and mice
that received THC for 2 years exhibited
body weight reductions, enhanced survival
rates, and decreased tumor incidences in
several sites, mainly organs under hormonal
control. These earlier experimental carcino-
genesis results on THC (3,4) clearly lend
further validity to the notion that cannabi-
noids may indeed be anticarcinogenic (1,2).
James Huff
Po Chan
National Institute of Environmental
Health Sciences
Research Triangle Park, North Carolina
E-mail: huff1@niehs.nih.gov 
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